Corona Virus – don’t panic. Advise by Dr. Klinghardt MD, PhD.
Dear Colleague, Dear patient! We all expect some day, in the not so distant future, that a pandemic will affect millions of people. And it does not matter, if it is intentionally spread by humans or if our good earth is striking out on her own. Today, it is the Corona-virus and it certainly will spread and leave its marks in the world. Here are some recommendation about caution and prevention:
The virus is known to spread through the breath, the mucous membranes including the eyes and other yet unknown routes.
- This means that we can keep our face protected by HOCL spray frequently throughout the day on the face, the mouth, the hands and any other exposed surface.
- From the medical literature it is clear that the approach using oral licorice and glycyrrhizic acid iv. is correct. We recommend 2 pipettes of the tincture 2-3 times a day for a solid prophylaxis, more, if you suspect that you are infected.
- If at all possible: use rectal ozone 2-3 times per week (or i.v.) to keep you redox systems awake
- Use a humidifier filled with HOCL at home and at your workplace to evaporate HOCL at least 15 minutes per room every couple of days
- Other than that, keep your vit C, vit A and vit D3 level as high as you can – and it will all brush over you!
I am wishing you all a healthy and safe winter!
Kindly, Yvette Frick ( student of Dr Klinghardt)
Licorice against the Corona virus
Cohen, Jeffrey I. “Licking latency with licorice.” The Journal of clinical investigation 115.3 (2005): 591-593.
Abstract: Numerous viruses cause latent infections in humans, and reactivation often results in pain and suffering. While vaccines for several of these viruses are available or currently being studied in clinical trials, and antiviral therapies have been successful in preventing or treating active infection, therapy to eradicate latent infection has lagged behind. A new study reported in this issue of the JCI shows that treatment of cells latently infected with Kaposi sarcoma–associated herpesvirus (KSHV) with glycyrrhizic acid, a component of licorice, reduces synthesis of a viral latency protein and induces apoptosis of infected cells. This finding suggests a novel way to interrupt latency.
Licorice, derived from the root of Glycyrrhiza glabra, has been used for more than 4 millennia as a flavoring agent in foods, beverages, and tobacco (1). Licorice is also used as an alternative medicine for the treatment of gastric and duodenal ulcers, sore throat, bronchitis, cough, arthritis, adrenal insufficiency, and allergic diseases. The licorice root contains numerous compounds, including glycyrrhizic acid (GA). It is estimated that in the United States, 3.3 mg of GA is consumed per person daily. GA inhibits the replication of several viruses in vitro including herpesviruses, HIV, and the SARS coronavirus. When taken orally, GA is hydrolyzed to glycyrrhetic acid by bacteria in the gastrointestinal tract before GA can be absorbed. Therefore, in Asia, where GA is used for the treatment of chronic hepatitis B or C infection, the drug is infused intravenously to achieve the appropriate serum levels.
Licorice against EBV:
Lin, Jung-Chung. “Mechanism of action of glycyrrhizic acid in inhibition of Epstein-Barr virus replication in vitro.” Antiviral research 59.1 (2003): 41-47.
Abstract: We report here that glycyrrhizic acid (GL), a component of licorice root (Glycyrrhiza radix), is active against EBV replication in superinfected Raji cells in a dose-dependent fashion. The IC50 values for viral inhibition and cell growth were 0.04 and 4.8 mM, respectively. The selectivity index (ratio of IC50 for cell growth to IC50 for viral DNA synthesis) was 120. Time of addition experiments suggested that GL interferes with an early step of EBV replication cycle (possibly penetration). GL had no effect on viral adsorption, nor did it inactivate EBV particles. Thus, GL represents a new class of anti-EBV compounds with a mode of action different from that of the nucleoside analogs that inhibit viral DNA polymerase.
Okamoto, Hitoshi, Daisuke Yoshida, and Shigenobu Mizusaki. “Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced induction in Epstein-Barr virus early antigen in Raji cells.” Cancer letters 19.1 (1983): 47-53.
Abstract: Retinol, 5 flavonoids, 3 steroids and 7 sweetening agents were studied for their effects on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced early antigen (EA) of Epstein-Barr virus (EBV) in Raji cells. Concomitant treatment of Raji cells with TPA and retinol showed inhibition of EA induction. Among flavonoids, quercetin resulted in effective inhibition of EA induction by TPA and α-naphthoflavone showed the weakly inhibitory effect. None of the other flavonoids such as rutin, catechin and β-naphthoflavone affected the induction of EBV-EA by TPA. β-Estradiol obviously inhibited EBV-EA induction by TPA, but hydrocortisone did not show any inhibitory effect on it. Glycyrrhetinic acid, steviol, phyllodulcin and perrillartine also showed the remarkable inhibition of EBV-EA induction. On the other hand, glycyrrhizin and stevioside, glycosides of glycyrrhetinic acid and steviol, did not inhibit the induction of EBV-EA by TPA. Some of the inhibitors reported here may be effective on the inhibition of the in vivo tumor promotion by TPA.